Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ATS Medical

This article was originally published in The Gray Sheet

Executive Summary

Plans to submit an investigational device exemption for its mechanical heart valve to FDA next month, company President and CEO Manuel Villafana tells the Dain Bosworth Healthcare Conference Sept. 19. The valve, designed to reduce clotting in valve replacement surgery patients, received regulatory approval in France last week. Villafana says that France represents the largest market outside the U.S. for the valve, which currently is available commercially in the U.K., Spain, Belgium, and Australia and is awaiting approval in Italy and Japan



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts